DDInter1943 DDInter1652
In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label].
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Vitamin E {u} (Compound) resembles {v} (Compound) Phylloquinone
Vitamin E {u} (Compound) binds {v} (Gene) NR1I2
Vitamin E {u} (Compound) upregulates {v} (Gene) CDK6
Vitamin E {u} (Compound) downregulates {v} (Gene) PTPRO
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mogamulizumab
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Infliximab
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mechlorethamine
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Vitamin E (Compound) resembles Phylloquinone (Compound)
Vitamin E (Compound) binds NR1I2 (Gene)
Vitamin E (Compound) upregulates CDK6 (Gene)
Vitamin E (Compound) downregulates PTPRO (Gene)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Infliximab
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide